证券代码：002772 证券简称：众兴菌业 公告编号：2024-045 天水众兴菌业科技股份有限公司 2024年半年度募集资金存放与使用情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天水众兴菌业科技股份有限公司（以下简称"公司"）于 2024 年 08 月 15 日 召开第五届董事会第三次会议及第五届监事会第三次会议审议通过了《关于<2024 年半年度募集资金存放与使用情况的专项报告>的议案》，现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准天水众兴菌业科技股份有限公司公开发 行可转换公司债券的批复》（证监许可【2017】2002 号）核准，公司于 2017 年 12 月 13 日公开发行 920 万张可转换公司债券，每张面值为人民币 100 元，按票面价 值平价发行，共募集资金 92,000 万元人民币，扣除发行费用后，实际募集资金净额 为 90,290 万元人民币。2017 年 12 月 19 日，上述资金到位情况业经中审众环会计 师事务所（特殊普通合伙）审验并出具了众环验字（2017）080011 号《验资报告 ...

天水众兴菌业科技股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 天水众兴菌业科技股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：天水众兴菌业科技股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方 | 占用方与上市公 | 上市公司核算 | 2024 年期初占 | 2024 年 1-6 月占用累 计发生金额（不含利 | 2024 年 1-6 月 占用资金的利 | 2024 年 1-6 月偿 | 2024 年半 年度末往 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | 司的关联关系 | 的会计科目 | 用资金余额 | 息） | 息（如有） | 还累计发生金额 | 来资金余 额 | | | | 控股股东、实际控制 | | | | | | | | | | 非经营性占用 | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | - ...

证券代码：002772 证券简称：众兴菌业 公告编号：2024-042 天水众兴菌业科技股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 天水众兴菌业科技股份有限公司（以下简称"公司"）第五届董事会第三次 会议于 2024 年 08 月 15 日在公司会议室现场召开。本次会议由公司董事长高博 书先生主持，会议通知已于 2024 年 08 月 04 日以电子邮件方式送达给全体董事 和高级管理人员。本次会议应出席董事 9 人，实际出席董事 9 人，公司监事、高 级管理人员列席了本次会议。 《2024 年半年度报告》、《2024 年半年度财务报告》及《2024 年半年度非 经营性资金占用及其他关联资金往来情况汇总表》详见公司指定信息披露媒体巨 1 / 3 潮资讯网（http://www.cninfo.com.cn）。《2024 年半年度报告摘要》（公告编号： 2024-044）详见公司指定的信息披露媒体《证券时报》、《上海证券报》和巨潮 资讯网（http://www.cninfo.com.cn）。 ...

天水众兴菌业科技股份有限公司 董事、监事和高级管理人员所持公司股份及其变动管理制度 天水众兴菌业科技股份有限公司 董事、监事和高级管理人员 所持公司股份及其变动管理制度 甘肃·天水 二○二四年八月 董事、监事和高级管理人员所持公司股份及其变动管理制度 第一章 总 则 第一条 为加强对天水众兴菌业科技股份有限公司（以下简称"公司"或"本 公司"）董事、监事和高级管理人员持有公司股票及其衍生品种变动的管理，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司董事、监事和高级管理人员 所持本公司股份及其变动管理规则》、《深圳证券交易所上市公司自律监管指引 第 10 号——股份变动管理》及《深圳证券交易所上市公司自律监管指引第 18 号 ——股东及董事、监事、高级管理人员减持股份》等法律、法规、部门规章、规 范性文件及《公司章程》等的有关规定，制定本制度。 第二条 本制度适用于公司董事、监事和高级管理人员及本制度第十九条规 定的自然人、法人或其他组织持有及变动公司股票及其衍生品种的管理。 本制度所称高级管理人员指公司总经理、副总经理、财务总监及董事 ...

证券代码：002772 证券简称：众兴菌业 公告编号：2024-046 天水众兴菌业科技股份有限公司 关于第一期员工持股计划存续期展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天水众兴菌业科技股份有限公司（以下简称"公司"）于 2024 年 08 月 15 日召开第五届董事会第三次会议审议通过了《关于第一期员工持股计划存续期展 期的议案》，同意将公司第一期员工持股计划的存续期展期 24 个月，即存续期 延长至 2026 年 08 月 31 日，现将具体情况公告如下： 一、公司第一期员工持股计划的基本情况 2020 年 07 月 24 日公司召开第三届董事会第三十三次会议、第三届监事会 第十九次会议及于 2020 年 08 月 12 日召开的 2020 年第二次临时股东大会审议通 过了《关于<天水众兴菌业科技股份有限公司第一期员工持股计划（草案）及其 摘要>的议案》、《关于<天水众兴菌业科技股份有限公司第一期员工持股计划 管理办法>的议案》等相关议案，本期员工持股计划股票来源为公司回购专用账 户（第一期）中回购股份。相关内容详见 2020 年 07 ...

证券代码：002772 证券简称：众兴菌业 公告编号：2024-043 天水众兴菌业科技股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 天水众兴菌业科技股份有限公司（以下简称"公司"）第五届监事会第三次 会议于2024年08月15日在公司会议室现场召开。召开本次会议的通知已于2024 年 08 月 04 日以电子邮件方式送达各位监事。 本次会议由监事会主席张天荣先生主持，会议应出席监事3名，实际出席3 名，会议召开程序及出席情况符合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真审议，本次会议以记名投票表决方式表决通过了以下议案： （一）审议通过了《关于公司<2024 年半年度报告全文及摘要>的议案》 表决情况：3 票同意、0 票反对、0 票弃权、0 票回避 表决结果：通过 监事会认为：董事会编制和审核公司《2024 年半年度报告》的程序符合法 律、法规及深圳证券交易所的相关规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥914,678,822.16, a decrease of 10.22% compared to ¥1,018,855,736.53 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was ¥29,478,836.92, down 85.07% from ¥197,475,000.63 in the previous year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥20,449,322.06, a decline of 89.29% compared to ¥190,961,355.62 in the same period last year[11]. - The net cash flow from operating activities was ¥180,800,164.60, a decrease of 44.46% from ¥325,536,843.68 in the previous year[11]. - Basic earnings per share were ¥0.0750, down 85.08% from ¥0.5026 in the same period last year[11]. - Diluted earnings per share were ¥0.0750, a decrease of 84.66% compared to ¥0.4889 in the previous year[11]. - The company's operating revenue for the reporting period was ¥914,678,822.16, a decrease of 10.22% compared to the same period last year, primarily due to a decline in the average selling price of enoki mushrooms[35]. - The company's operating costs increased by 8.09% to ¥752,644,921.45, attributed to an increase in production and sales volume compared to the previous year[35]. - The company reported a significant increase of 21.80% in financial expenses to ¥22,059,285.39, mainly due to fluctuations in exchange gains and losses[35]. Revenue Breakdown - Revenue from agricultural planting was ¥913,748,195.18, accounting for 99.90% of total revenue, down 10.32% year-on-year[37]. - Revenue from the product "Golden Needle Mushroom" was ¥381,642,812.82, a decline of 29.22% from ¥539,211,911.55 in the previous year[36]. - Revenue from "Button Mushroom" increased by 10.16% to ¥524,548,998.16, compared to ¥476,152,212.42 last year[36]. - The company experienced a significant increase in revenue from "Cordyceps" by 116.42%, reaching ¥7,556,384.20 compared to ¥3,491,612.56 last year[36]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,172,257,763.78, an increase of 1.62% from ¥6,073,765,300.40 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company were ¥3,343,995,387.42, down 2.58% from ¥3,432,488,958.20 at the end of the previous year[11]. - Cash and cash equivalents at the end of the reporting period were ¥1,244,675,833.39, representing 20.17% of total assets, an increase from 17.10% last year[39]. - Short-term borrowings increased to ¥456,332,856.22, accounting for 7.39% of total liabilities, up from 5.11% last year[40]. - Long-term borrowings rose to ¥1,444,270,950.61, making up 23.40% of total liabilities, compared to 17.69% at the end of the previous year[40]. Investment and Subsidiaries - The company established a new subsidiary, Xinxiang Zhongxing Biotechnology Co., Ltd., with an investment of CNY 5,000,000, holding a 100% stake[46]. - The company also set up Tianjin Zhongxing Investment Co., Ltd. with an investment of CNY 10,000,000, also holding a 100% stake[46]. - The company reported a loss of CNY 1,204,142.41 from its investment in Tianshui Jinxing Biotechnology Co., Ltd.[45]. - The company has successfully transferred the rights to 4 new varieties of button mushrooms from the Fujian Academy of Agricultural Sciences, further strengthening its product portfolio[29]. Research and Development - Research and development expenses rose by 17.14% to ¥6,974,968.15, mainly due to increased investment in R&D materials and personnel salaries[35]. - The company added 4 new patents during the reporting period, while 3 patents expired, with no significant changes in other intangible assets[29]. Market and Sales Strategy - The sales price of enoki mushrooms decreased by approximately 42% compared to the same period last year, significantly impacting profitability[20]. - The company employs a factory-based production model, allowing for year-round production and stable supply, mitigating market risks[22]. - The procurement strategy emphasizes quality and cost control, ensuring stable production through effective supplier management[24]. - The sales model primarily relies on distributors, with ongoing exploration of new sales channels to enhance market presence[26]. Environmental and Safety Compliance - The company has obtained pollution discharge permits valid until December 10, 2027, for its main facility[75]. - The wastewater treatment facility has a processing capacity of 600 m³/d and operates under the A/O biological contact oxidation process[76]. - The company reported no exceedances in wastewater discharge standards for key pollutants such as CODcr and BOD5[76]. - The company adheres to multiple environmental protection laws and standards, including the Environmental Protection Law and the Air Pollution Prevention Law[73]. Governance and Shareholder Matters - The company held its first extraordinary general meeting in 2024 with a participation rate of 38.36% and the annual general meeting with a participation rate of 38.39%[66]. - The company did not distribute cash dividends or issue bonus shares during the reporting period, nor did it increase capital through reserves[68]. - The employee stock ownership plan includes 269 employees holding a total of 9,000,000 shares, representing 2.29% of the company's total equity[68]. - The company appointed new independent directors and a deputy general manager on April 16, 2024, following the expiration of terms for several board members[67]. Risk Management - The company faces risks from industry competition leading to price declines, with increased market supply from new entrants affecting profitability[58]. - To mitigate risks, the company plans to enhance brand influence and product quality, focusing on green and safe consumption concepts[58]. - Seasonal fluctuations in sales prices and profits are a concern, with the second quarter traditionally being a low-demand period for mushrooms[59]. - The company aims to diversify its product offerings and extend its supply chain to reduce the impact of seasonal volatility on financial performance[59]. Financial Management - The company has entrusted financial management with a total amount of 330 million CNY, with an outstanding balance of 310 million CNY[103]. - The company has no overdue amounts in its entrusted financial management[103]. - The company has engaged in fixed income asset management plans totaling 30 million CNY, with no amounts recovered yet[104][106]. Accounting Policies - The company’s financial statements comply with the requirements of the accounting standards and reflect the financial position as of June 30, 2024[164]. - The company’s revenue recognition policies are tailored to its operational characteristics, adhering to relevant accounting standards[163]. - The company classifies financial assets into three categories: measured at amortized cost, measured at fair value with changes recognized in other comprehensive income, and measured at fair value with changes recognized in profit or loss[182].

证券代码：002772 证券简称：众兴菌业 公告编号：2024-041 （二）本次股东股份解除质押基本情况 单位：股 补充质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天水众兴菌业科技股份有限公司（以下简称"公司"）于 2024 年 07 月 15 日收到公司控股股东、实际控制人陶军先生的函告，获悉陶军先生将其持有的公 司部分股份办理了质押、补充质押及解除质押手续，现将具体情况公告如下： 一、股东部分股份质押、补充质押及解除质押基本情况 （一）本次股东股份质押基本情况 单位：股 | 股东 | 是否为控股 股东或第一 | 本次质押 | 占其所持 | 占公司总 | 是否为限售 股（如是， | 是否为 | 质押起 | 质押到 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 数量 | 股份比例 | 股本比例 | 注明限售类 | 补充质 | 始日 | 期日 | 质权人 | 用途 | | | 一致行动人 | | | ...

证券代码：002772 证券简称：众兴菌业 公告编号：2024-040 天水众兴菌业科技股份有限公司 关于控股股东、实际控制人部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天水众兴菌业科技股份有限公司（以下简称"公司"）于 2024 年 07 月 10 日收到公司控股股东、实际控制人陶军先生的函告，获悉陶军先生将其持有的公 司部分股份办理了质押及解除质押手续，现将具体情况公告如下： 一、股东部分股份质押及解除质押基本情况 （一）本次股东股份质押基本情况 单位：股 | 股东 | 是否为控股股东或第一大 | 本次解除质 | 占其所持 | 占公司总 | 质押起始日 | 解除质押日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股东及其一致行动人 | 押股份数量 | 股份比例 | 股本比例 | | | | | 陶 军 | 是 | 25,000,000 | 22.6992% | 6.3574% | 2023 年 6 月 30 日 | 2024 年 7 月 ...

Topic 1: Financial Performance - Net profit attributable to shareholders of the listed company is expected to be between 29 million yuan and 34 million yuan, a year-on-year decrease of 82.78% to 85.31%[2] - Net profit after deducting non-recurring gains and losses is expected to be between 22 million yuan and 27 million yuan, a year-on-year decrease of 85.86% to 88.48%[2] - Basic earnings per share are expected to be between 0.07 yuan and 0.09 yuan, compared to 0.50 yuan in the same period last year[2] Topic 2: Product Sales and Pricing - The sales price of the company's enoki mushroom products decreased by approximately 56% year-on-year in the first quarter and by approximately 42% year-on-year in the reporting period[14] Topic 3: Strategic Focus and Cost Management - The company will focus on improving product quality, increasing yield, and strengthening the brand to reduce costs and enhance competitiveness[14]